Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dystonia: treatment with bromocriptine.

R P Newman, P A LeWitt, C Shults

    Clinical Neuropharmacology
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The cardiovascular effects of bromocriptine in Parkinsonism.

    British journal of clinical pharmacology·2012
    Same author

    Parkinsonism-physiology and pharmacology.

    British medical journal·2010
    Same author

    German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia - Longitudinal observations.

    Parkinsonism & related disorders·2008
    Same author

    The role of the Lewy body in idiopathic Parkinsonism.

    Parkinsonism & related disorders·2008
    Same author

    The natural history of neurological manganism over 18 years.

    Parkinsonism & related disorders·2006
    Same author

    Autosomal dominant dystonia-plus with cerebral calcifications.

    Neurology·2006

    Bromocriptine, a dopaminomimetic agent, showed potential for improving symptoms in patients with dystonic disorders. This study explored its effects on various dystonia types, suggesting a role in managing these conditions.

    Area of Science:

    • Neurology
    • Neuropharmacology

    Background:

    • Dystonia, a movement disorder, shares potential dopaminergic neurotransmission disturbances with parkinsonism.
    • Dopaminergic pathways are implicated in the pathophysiology of certain dystonic conditions.

    Purpose of the Study:

    • To investigate the efficacy of bromocriptine, a dopaminomimetic agent, in treating various dystonic disorders.
    • To assess the symptomatic improvement in patients with dystonia using bromocriptine.

    Main Methods:

    • A double-blind, crossover study was conducted on 15 patients diagnosed with different types of dystonia.
    • Patients received bromocriptine at doses ranging from 18-150 mg/day (mean 72.5 mg/day).

    Main Results:

    • Out of 13 patients who completed the study, seven showed over 10% improvement in clinical ratings.

    Related Experiment Videos

  • Five patients reported subjective improvement in their disability.
  • Two patients experienced worsening of symptoms during the medication period.

    • Conclusions:

    • Bromocriptine, at doses effective for parkinsonism, may offer symptomatic benefits for specific patterns of dystonia.
    • Dopaminomimetic therapy warrants consideration for managing certain dystonic disorders.